(MENAFN- GlobeNewsWire - Nasdaq) Veteran FDA and Industry Leader to Guide Late-Stage Programs, Including First-In-Class Non-Addictive Analgesic DMX-101 SAN FRANCISCO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ...
SAN FRANCISCO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc. (“DIMERx”), a clinical-stage biopharmaceutical company developing first-in-class dimer-based therapeutics for major public-health needs, ...
SAN FRANCISCO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc. ("DIMERx”), a clinical-stage biopharmaceutical company developing first-in-class dimer-based therapeutics for major public-health needs, ...
No matter your current running pace and typical distance, in How to Run Faster, certified run coach Matt Meyer and other experts will help you speed up! You will learn crucial speed workouts, ...
Computer programming powers modern society and enabled the artificial intelligence revolution, but little is known about how our brains learn this essential skill. To help answer that question, Johns ...
Hosted on MSN
How DMX Turned Jay-Z’s Tour Into Chaos
What started as a powerhouse lineup became a battle for dominance. Jay-Z admits that inviting DMX on tour pushed him harder than any rival ever had—and changed him forever. Breaking: Trump says FBI is ...
Cross-generational collaborations where one of the acts involved is deceased are always tricky. It’s hard to know whether the decedent would actually have approved their voice pairing with the ...
Amicus Therapeutics (NASDAQ:FOLD) was upgraded to Buy from Hold at Needham with a $14 target, emphasizing that the company's kidney disease program, DMX-200, is undervalued. The stock of the company ...
Amicus Therapeutics FOLD reported adjusted earnings of 1 cent per share for the second quarter of 2025, which missed the Zacks Consensus Estimate of 2 cents. The company had incurred a loss of 6 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback